(RTTNews) - Cogent Biosciences, Inc. (COGT), a clinical-stage biotechnology company, announced the completion of the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Bezuclastinib in patients with Gastrointestinal Stromal Tumours (GI
1 views
Cogent Submits NDA For Bezuclastinib In GIS Tumours After Non-AdvSM; Eyes NDA For AdvSM In H1,2026
(RTTNews) - Cogent Biosciences, Inc. (COGT), a clinical-stage biotechnology company, announced the completion of the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for…
